Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 446	$ 189
Operating expenses:
Cost of revenue	1,346	369
Sales and marketing	4,539	3,925
General and administrative	10,018	9,475
Amortization of acquired intangible assets	505	123
Research and development	4,439	5,932
Total operating expenses	20,847	19,824
Operating loss	(20,401)	(19,635)
Other income (expense):
Interest income	121	2
Interest expense	(183)
Change in fair value - Senior Secured Convertible Notes	(1,040)
Loss on issue and offering costs - Senior Secured Convertible Note	(1,186)
Debt extinguishments loss - Senior Secured Convertible Notes	(525)
Gain on sale of intellectual property	1,000
Other income (expense), net	(1,813)	2
Loss before provision for income tax	(22,214)	(19,633)
Provision for income taxes
Net loss before noncontrolling interests	(22,214)	(19,633)
Net loss attributable to the noncontrolling interests	4,283	2,761
Net loss attributable to PAVmed Inc.	(17,931)	(16,872)
Less: Series B Convertible Preferred Stock dividends earned	(74)	(68)
Net loss attributable to PAVmed Inc. common stockholders	$ (18,005)	$ (16,940)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted	$ (0.18)	$ (0.20)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted	$ (0.19)	$ (0.20)
Weighted average common shares outstanding, basic and diluted	97,095,156	86,336,427